fda approval for tirzepatide TrimRX FDA approval for Zepbound: FSU

Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 trial results demonstrating 25% weight loss in half of people with #obesity

This article explains the clinical rationale, how biomarkers inform dosing decisions, and why gradual adjustment reduces side effects while maximizing therapeutic benefit

We should still examine these patients properly, since a change in smell or taste can point to other things too, and it would be a mistake to assume the drug is the cause without checking

See risks & benefits

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for the treatment of type 2 diabetes and obesity, may modulate pathways associated with the hallmarks of aging

Many people on GLP-1 medications hit a weight loss plateau